

chain nodes :

11 12 13

ring nodes :

1 2 3 4 5 6 7 8 9 10 14 15 16 17 18 19 21 22 23 24 25 26

chain bonds :

11-12 11-13 11-15

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 14-15 14-19 15-16 16-17  
17-18 18-19 21-22 21-26 22-23 23-24 24-25 25-26

exact/norm bonds :

11-12 11-13 11-15 21-22 21-26 22-23 23-24 24-25 25-26

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 14-15 14-19 15-16 16-17  
17-18 18-19

isolated ring systems :

containing 21 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS  
12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:CLASS  
21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:CLASS

10/509078

\$%^STN;HighlightOn=;HighlightOff=;Version Version = STN Express 8.01a;

=> s l1

SAMPLE SEARCH INITIATED 12:13:53 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 313 TO ITERATE

100.0% PROCESSED 313 ITERATIONS

4 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 5199 TO 7321

PROJECTED ANSWERS: 4 TO 200

L2 4 SEA SSS SAM L1

=> d 12 1-4

L2 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN

RN 848396-04-3 REGISTRY

ED Entered STN: 13 Apr 2005


CN Quinoline, 8-[4-(cyclopropylmethyl)-1-piperazinyl]-3-(phenylsulfonyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)

MF C23 H25 N3 O2 S . Cl H

SR CA

LC STN Files: CA, CAPLUS, CASREACT, USPATFULL

CRN (848396-14-5)



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN

RN 607743-50-0 REGISTRY

ED Entered STN: 22 Oct 2003


CN Quinoline, 3-[(3-fluorophenyl)sulfonyl]-8-(1-piperazinyl)- (9CI) (CA  
INDEX NAME)

MF C19 H18 F N3 O2 S

CI COM

10/509078


SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 607742-78-9 REGISTRY  
ED Entered STN: 22 Oct 2003  
CN Quinoline, 3-[(4-methylphenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)- (9CI)  
(CA INDEX NAME)  
MF C21 H23 N3 O2 S  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 607742-63-2 REGISTRY  
ED Entered STN: 22 Oct 2003  
CN Quinoline, 7-chloro-3-(phenylsulfonyl)-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)  
MF C19 H18 Cl N3 O2 S . Cl H  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL  
CRN (607743-53-3)

10/509078



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s l1 sss full  
FULL SEARCH INITIATED 12:14:12 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 6089 TO ITERATE

100.0% PROCESSED 6089 ITERATIONS 90 ANSWERS  
SEARCH TIME: 00.00.01

L3 90 SEA SSS FUL L1

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	180.35	180.56

FILE 'CAPLUS' ENTERED AT 12:14:19 ON 01 APR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Apr 2007 VOL 146 ISS 15  
FILE LAST UPDATED: 30 Mar 2007 (20070330/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3


10/509078

L4 5 L3

=> d l4 1-5 bib abs hitstr

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:493996 CAPLUS  
DN 145:8187  
TI Preparation of isotopomeric piperazine-containing ligands labeling and  
diagnostic imaging of 5-HT6 receptors  
IN Gee, Antony David; Martarello, Laurent; Johnson, Christopher Norbert;  
Witty, David R.  
PA Glaxo Group Limited, UK  
SO PCT Int. Appl., 17 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006053785	A1	20060526	WO 2005-EP12463	20051117
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	GB 2004-25548	A	20041119		
OS	MARPAT 145:8187				
GI					




AB Piperazine-containing ligands [I; R1 = 3H, 11C, 13N, 15O, 76Br, 18 F, 123I, 125I, 131I, 75Br, 76Br, 77Br, 82Br, 211At; R2 = F; or R1 = Cl-4 (fluoro)alkyl and R2 = 3H, 11C, 13N, 15O, 76Br, 18 F, 123I, 125I, 131I, 75Br, 76Br, 77Br, 82Br, 211At; e.g., (11C-N-methyl)-3-[(3-fluorophenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)quinoline; 5-HT6 receptor pKi 9.82], which are useful for the labeling and diagnostic imaging of 5-HT6 receptors functionality and the treatment of CNS related disorders, are prepared  
IT 607743-50-0  
RL: RCT (Reactant); RACT (Reactant or reagent)

10/509078

(in the preparation of isotopomeric piperazine-containing ligands labeling  
and  
diagnostic imaging of 5-HT6 receptors)  
RN 607743-50-0 CAPLUS  
CN Quinoline, 3-[(3-fluorophenyl)sulfonyl]-8-(1-piperazinyl)- (9CI) (CA  
INDEX NAME)



IT 887923-36-6P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
(preparation of isotopomeric piperazine-containing ligands labeling and  
diagnostic imaging of 5-HT6 receptors)  
RN 887923-36-6 CAPLUS  
CN Quinoline, 3-[(3-fluorophenyl)sulfonyl]-8-[4-(methyl-11C)-1-piperazinyl]-  
(9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN.  
AN 2005:395276 CAPLUS  
DN 142:430310  
TI Process for the preparation of a crystal polymorphic form of  
3-phenylsulfonyl-8-piperazin-1-ylquinoline  
IN Gladwin, Asa Elisabeth  
PA Glaxo Group Limited, UK  
SO PCT Int. Appl., 18 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.


KIND

DATE

APPLICATION NO.

DATE

PI	WO 2005040124	A1	20050506	WO 2004-EP10843	20040923
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004283805	A1	20050506	AU 2004-283805	20040923
	CA 2540022	A1	20050506	CA 2004-2540022	20040923
	EP 1667975	A1	20060614	EP 2004-765655	20040923
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1856471	A	20061101	CN 2004-80027527	20040923
	BR 2004014678	A	20061128	BR 2004-14678	20040923
	JP 2007506702	T	20070322	JP 2006-527373	20040923
	US 2007032504	A1	20070208	US 2006-572670	20060320
	NO 2006001791	A	20060424	NO 2006-1791	20060424
PRAI	GB 2003-22629	A	20030926		
	WO 2004-EP10843	W	20040923		
OS	CASREACT 142:430310				
AB	Polymorphic crystalline forms of 3-phenylsulfonyl-8-piperazin-1-ylquinoline are synthesized, characterized, and claimed in the treatment of CNS (e.g., schizophrenia) and other disorders.				
IT	607742-69-8P, 3-Phenylsulfonyl-8-piperazin-1-ylquinoline RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (process for the preparation of a crystal polymorphic form of 3-phenylsulfonyl-8-piperazin-1-ylquinoline)				
RN	607742-69-8 CAPLUS				
CN	Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)				




RE.CNT 1      THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4    ANSWER 3 OF 5    CAPLUS    COPYRIGHT 2007 ACS on STN  
 AN    2005:260030    CAPLUS  
 DN    142:336394  
 TI    Preparation of 8-(1-piperazinyl)quinolines for treatment of CNS disorders  
 IN    Johnson, Christopher Norbert; Witty, David R.  
 PA    Glaxo Group Limited, UK  
 SO    PCT Int. Appl., 33 pp.  
      CODEN: PIXXD2

10/509078

DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005026125	A1	20050324	WO 2004-EP10129	20040909
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1663980	A1	20060607	EP 2004-765057	20040909
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2007505075	T	20070308	JP 2006-525773	20040909
	US 2006287334	A1	20061221	US 2006-571405	20060310
PRAI	GB 2003-21473	A	20030912		
	WO 2004-EP10129	W	20040909		
OS	CASREACT 142:336394; MARPAT 142:336394				
GI					



AB Title compds. I [R<sup>1</sup> = (un)substituted alkyl, alkylcycloalkyl, alkoxyalkyl, alkyl(hetero)aryl, alkylheterocyclyl; R<sup>2</sup> = H or alkyl; m = 1-4; when m > 1, two R<sup>2</sup> groups may be linked to form a CH<sub>2</sub>, (CH<sub>2</sub>)<sub>2</sub> or (CH<sub>2</sub>)<sub>3</sub> group; R<sup>3</sup>-R<sup>5</sup> = independently H, halo, CN, CF<sub>3</sub>, OCF<sub>3</sub>, alkyl, alkoxy, alkanoyl, CONH<sub>2</sub> and derivs.; n = 1 - 3; p = 1-2; and their pharmaceutically acceptable salts] were prepared as 5HT<sub>6</sub> receptor antagonists in treatment of CNS disorders. Thus, condensation of 3-phenylsulfonyl-8-(piperazin-1-yl)quinoline (preparation given) with 4-fluorobenzaldehyde gave II. I were tested and showed good affinity for the 5-HT<sub>6</sub> receptor, having pK<sub>i</sub> values ≥ 7.0 at human cloned 5-HT<sub>6</sub> receptors.

IT 848396-13-4P, 8-[4-(4-Fluorobenzyl)piperazin-1-yl]-3-phenylsulfonylquinoline  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)




10/509078

(preparation of 8-(1-piperazinyl)quinolines for treatment of CNS disorders)

RN 848396-13-4 CAPLUS

CN Quinoline, 8-[4-[(4-fluorophenyl)methyl]-1-piperazinyl]-3-(phenylsulfonyl)-  
(9CI) (CA INDEX NAME)




IT 848396-03-2P, 8-[4-(4-Fluorobenzyl)piperazin-1-yl]-3-phenylsulfonylquinoline hydrochloride 848396-04-3P, 8-(4-Cyclopropylmethylpiperazin-1-yl)-3-phenylsulfonylquinoline hydrochloride 848396-05-4P, 8-[4-(Cyclohexyl)piperazin-1-yl]-3-phenylsulfonylquinoline hydrochloride 848396-07-6P, 8-(4-Cyclopentylpiperazin-1-yl)-3-phenylsulfonylquinoline hydrochloride 848396-08-7P, 8-(4-Cyclobutylpiperazin-1-yl)-3-phenylsulfonylquinoline hydrochloride 848396-09-8P, 8-(4-Cyclopropylpiperazin-1-yl)-3-phenylsulfonylquinoline hydrochloride 848396-11-2P, 8-[4-(2-Methoxyethyl)piperazin-1-yl]-3-phenylsulfonylquinoline hydrochloride 848396-12-3P, 8-[4-(2,2,2-Trifluoroethyl)piperazin-1-yl]-3-(4-fluorophenylsulfonyl)quinoline 848396-14-5P, 8-(4-Cyclopropylmethylpiperazin-1-yl)-3-phenylsulfonylquinoline 848396-15-6P, 8-[4-(Cyclohexyl)piperazin-1-yl]-3-phenylsulfonylquinoline 848396-16-7P, 8-(4-Cyclopentylpiperazin-1-yl)-3-phenylsulfonylquinoline 848396-17-8P, 8-(4-Cyclobutylpiperazin-1-yl)-3-phenylsulfonylquinoline 848396-18-9P, 8-(4-Cyclopropylpiperazin-1-yl)-3-phenylsulfonylquinoline 848396-19-0P, 8-[4-(2-Methoxyethyl)piperazin-1-yl]-3-phenylsulfonylquinoline  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 8-(1-piperazinyl)quinolines for treatment of CNS disorders)

RN 848396-03-2 CAPLUS


CN Quinoline, 8-[4-[(4-fluorophenyl)methyl]-1-piperazinyl]-3-(phenylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)

10/509078



● HCl


RN 848396-04-3 CAPLUS  
CN Quinoline, 8-[4-(cyclopropylmethyl)-1-piperazinyl]-3-(phenylsulfonyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848396-05-4 CAPLUS  
CN Quinoline, 8-(4-cyclohexyl-1-piperazinyl)-3-(phenylsulfonyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)


10/509078



● HCl

RN 848396-07-6 CAPLUS

CN Quinoline, 8-(4-cyclopentyl-1-piperazinyl)-3-(phenylsulfonyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 848396-08-7 CAPLUS


CN Quinoline, 8-(4-cyclobutyl-1-piperazinyl)-3-(phenylsulfonyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)

10/509078



● HCl


RN 848396-09-8 CAPLUS  
CN Quinoline, 8-(4-cyclopropyl-1-piperazinyl)-3-(phenylsulfonyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848396-11-2 CAPLUS  
CN Quinoline, 8-[4-(2-methoxyethyl)-1-piperazinyl]-3-(phenylsulfonyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)


10/509078



● HCl


RN 848396-12-3 CAPLUS

CN Quinoline, 3-[(4-fluorophenyl)sulfonyl]-8-[4-(2,2,2-trifluoroethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 848396-14-5 CAPLUS


CN Quinoline, 8-[4-(cyclopropylmethyl)-1-piperazinyl]-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



10/509078


RN 848396-15-6 CAPLUS

CN Quinoline, 8-(4-cyclohexyl-1-piperazinyl)-3-(phenylsulfonyl)- (9CI) (CA  
INDEX NAME)



RN 848396-16-7 CAPLUS


CN Quinoline, 8-(4-cyclopentyl-1-piperazinyl)-3-(phenylsulfonyl)- (9CI) (CA  
INDEX NAME)



RN 848396-17-8 CAPLUS


CN Quinoline, 8-(4-cyclobutyl-1-piperazinyl)-3-(phenylsulfonyl)- (9CI) (CA  
INDEX NAME)

10/509078




RN 848396-18-9 CAPLUS

CN Quinoline, 8-(4-cyclopropyl-1-piperazinyl)-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 848396-19-0 CAPLUS

CN Quinoline, 8-[4-(2-methoxyethyl)-1-piperazinyl]-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



IT 607742-54-1P, 8-(4-Methylpiperazin-1-yl)-3-phenylsulfonylquinoline  
607742-55-2P, 3-Phenylsulfonyl-8-(piperazin-1-yl)quinoline  
hydrochloride 607742-69-8P, 3-Phenylsulfonyl-8-(piperazin-1-yl)quinoline  
607743-10-2P, 8-(4-tert-Butoxycarbonylpiperazin-1-yl)-3-phenylsulfonylquinoline  
607743-42-0P, 8-(4-Methylpiperazin-

10/509078


1-yl)-3-phenylsulfonylquinoline hydrochloride

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of 8-(1-piperazinyl)quinolines for treatment of CNS disorders)


RN 607742-54-1 CAPLUS

CN Quinoline, 8-(4-methyl-1-piperazinyl)-3-(phenylsulfonyl)- (9CI) (CA INDEX  
NAME)



RN 607742-55-2 CAPLUS

CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)-, monohydrochloride (9CI)  
(CA INDEX NAME)




● HCl

RN 607742-69-8 CAPLUS

CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)




10/509078




RN 607743-10-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-(phenylsulfonyl)-8-quinolinyl]-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 607743-42-0 CAPLUS

CN Quinoline, 8-(4-methyl-1-piperazinyl)-3-(phenylsulfonyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

10/509078

RE.CNT 8      THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4    ANSWER 4 OF 5    CAPLUS    COPYRIGHT 2007 ACS on STN  
AN    2003:777791    CAPLUS  
DN    139:292272  
TI    Preparation of arylsulfonylquinolinyl- of azaindolylpiperazines as 5-HT6  
      antagonists  
IN    Johnson, Christopher Norbert; MacDonald, Gregor James; Mitchell, Darren  
      Jason; Moss, Stephen Frederick; Thompson, Mervyn; Witty, David  
PA    Glaxo Group Limited, UK  
SO    PCT Int. Appl., 30 pp.  
      CODEN: PIXXD2  
DT    Patent  
LA    English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003080608	A2	20031002	WO 2003-EP3195	20030325
	WO 2003080608	A3	20040205		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
	PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,				
	UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003226724	A1	20031008	AU 2003-226724	20030325
	EP 1497291	A2	20050119	EP 2003-744860	20030325
	EP 1497291	B1	20061122		
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005124626	A1	20050609	US 2003-509077	20030325
	JP 2005527542	T	20050915	JP 2003-578362	20030325
	AT 346068	T	20061215	AT 2003-744860	20030325
PRAI	GB 2002-7275	A	20020327		
	GB 2002-7278	A	20020327		
	GB 2002-7281	A	20020327		
	GB 2002-7282	A	20020327		
	WO 2003-EP3195	W	20030325		
OS	MARPAT 139:292272				
GI					



AB    Title compds. I [R1, R2 = H, alkyl; R1R2, R22 = (CH2)1-4; Q =

10/509078


(un)substituted quinolinyl, pyrrolopyridinyl; A = (un)substituted aryl; m = 1-4; p = 1, 2] were prepared for use as 5-HT<sub>6</sub> antagonists in the treatment of CNS and other disorders. Thus, 3-chloro-4-nitropyridine was treated with 1-tert.-butoxycarbonylpiperazine, cyclized with CH<sub>2</sub>:CHMgBr to 7-tert.-butoxycarbonylpiperazin-1-yl-1H-pyrrolo[3,2-b]pyridine, which was treated with Ph<sub>2</sub>S<sub>2</sub>, oxidized to the sulfone. and deblocked to give the title compound II.

IT 608142-86-5P 608142-88-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of arylsulfonylquinolinyl- of azaindolylpiperazines as 5-HT<sub>6</sub> antagonists)


RN 608142-86-5 CAPLUS

CN Quinoline, 4-(phenylsulfonyl)-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 608142-88-7 CAPLUS

CN Quinoline, 2-methyl-4-(phenylsulfonyl)-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)



IT 608142-87-6P 608142-89-8P 608142-90-1P

608142-91-2P 608142-92-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of arylsulfonylquinolinyl- of azaindolylpiperazines as 5-HT<sub>6</sub> antagonists)

RN 608142-87-6 CAPLUS

CN Quinoline, 4-(phenylsulfonyl)-8-(1-piperazinyl)-, monohydrochloride (9CI)

10/509078


(CA INDEX NAME)



● HCl

RN 608142-89-8. CAPLUS

CN Quinoline, 2-methyl-4-(phenylsulfonyl)-8-(1-piperazinyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 608142-90-1 CAPLUS

CN Quinoline, 4-[(2-fluorophenyl)sulfonyl]-2-methyl-8-(1-piperazinyl)- (9CI)  
(CA INDEX NAME)

10/509078




RN 608142-91-2 CAPLUS  
CN Quinoline, 4-[(3-fluorophenyl)sulfonyl]-2-methyl-8-(1-piperazinyl)- (9CI)  
(CA INDEX NAME)




RN 608142-92-3 CAPLUS  
CN Quinoline, 4-[(3-chlorophenyl)sulfonyl]-2-methyl-8-(1-piperazinyl)- (9CI)  
(CA INDEX NAME)


10/509078



IT 608143-05-1P 608143-10-8P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of arylsulfonylquinolinyl- of azaindolylpiperazines as 5-HT6  
antagonists)  
RN 608143-05-1 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[4-(phenylsulfonyl)-8-quinolinyl]-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 608143-10-8 CAPLUS  
CN Piperazine, 1-[2-methyl-4-(phenylsulfonyl)-8-quinolinyl]-4-  
(trifluoroacetyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:777764 CAPLUS  
 DN 139:292163  
 TI Preparation of arylsulfonyl(diazacycloalkyl)quinolines for treatment of  
 CNS disorders  
 IN Ahmed, Mahmood; Johnson, Christopher Norbert; Jones, Martin C.; MacDonald,  
 Gregor James; Moss, Stephen Frederick; Thompson, Mervyn; Wade, Charles  
 Edward; Witty, David  
 PA Glaxo Group Limited, UK  
 SO PCT Int. Appl., 48 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003080580	A2	20031002	WO 2003-EP3197	20030325
	WO 2003080580	A3	20040205		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
	PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,				
	UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2479786	A1	20031002	CA 2003-2479786	20030325
	AU 2003219103	A1	20031008	AU 2003-219103	20030325
	EP 1497266	A2	20050119	EP 2003-714889	20030325
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003008696	A	20050125	BR 2003-8696	20030325
	US 2005124628	A1	20050609	US 2003-509078	20030325
	CN 1656075	A	20050817	CN 2003-811644	20030325
	JP 2005531518	T	20051020	JP 2003-578335	20030325
	ZA 2004007320	A	20051004	ZA 2004-7320	20040912
	NO 2004004588	A	20041025	NO 2004-4588	20041025
PRAI	GB 2002-7289	A	20020327		
	GB 2002-25678	A	20021104		
	WO 2003-EP3197	W	20030325		

10/509078


OS MARPAT 139:292163  
GI



AB Title compds. I [R1, R2 = H, alkyl; R1R2, R22 = (CH2)2-4; R3-R5 = H, halogen, CN, CF3, OCF3, alkyl, alkoxy, alkanoyl, (un)substituted CONH2; A = (un)substituted aryl; m = 1-4; n = 1-3, p = 1, 2] were prepared for use as HT6 receptor antagonists in treatment of CNS disorders. Thus, 8-iodo-3-phenylsulfonylquinoline was prepared from 8-nitroquinoline and was treated with 1-tert.-butoxycarbonylpiperazine, followed by deblocking, to give 3-phenylsulfonyl-8-piperazinoquinoline.

IT 607743-10-2P 607743-11-3P 607743-43-1P  
607743-44-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of arylsulfonyl(diazacycloalkyl)quinolines for treatment of CNS disorders)


RN 607743-10-2 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[3-(phenylsulfonyl)-8-quinolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 607743-11-3 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[3-[[3-(trifluoromethyl)phenyl]sulfonyl]-8-quinolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



10/509078




RN 607743-43-1 CAPLUS  
CN Quinoline, 3-[(2-chlorophenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)- (9CI)  
(CA INDEX NAME)



RN 607743-44-2 CAPLUS  
CN 1-Piperazinecarboxylic acid, 3-methyl-4-[3-(phenylsulfonyl)-8-quinolinyl]-  
, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 607742-55-2P 607742-69-8P


10/509078

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);  
USES (Uses)

(preparation of arylsulfonyl(diazacycloalkyl)quinolines for treatment of CNS disorders)

RN 607742-55-2 CAPLUS


CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)-, monohydrochloride (9CI)  
(CA INDEX NAME)



● HCl

RN 607742-69-8 CAPLUS

CN Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)



IT 607742-54-1P 607742-56-3P 607742-57-4P  
607742-58-5P 607742-59-6P 607742-60-9P  
607742-61-0P 607742-62-1P 607742-63-2P  
607742-64-3P 607742-65-4P 607742-66-5P  
607742-68-7P 607742-70-1P 607742-71-2P  
607742-72-3P 607742-73-4P 607742-74-5P  
607742-75-6P 607742-76-7P 607742-77-8P  
607742-78-9P 607742-79-0P 607742-80-3P  
607742-81-4P 607742-82-5P 607742-83-6P  
607742-84-7P 607742-85-8P 607742-86-9P  
607742-87-0P 607742-88-1P 607742-89-2P  
607742-90-5P 607742-92-7P 607742-93-8P  
607742-94-9P 607742-95-0P 607742-96-1P  
607742-97-2P 607742-99-4P 607743-00-0P  
607743-01-1P 607743-02-2P 607743-03-3P  
607743-42-0P 607743-46-4P 607743-47-5P  
607743-48-6P 607743-49-7P 607743-50-0P

10/509078

607743-51-1P 607743-52-2P 607743-53-3P

607743-54-4P 607743-55-5P 607743-56-6P


607743-58-8P 607743-59-9P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylsulfonyl(diazacycloalkyl)quinolines for treatment of CNS disorders)


RN 607742-54-1 CAPLUS

CN Quinoline, 8-(4-methyl-1-piperazinyl)-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 607742-56-3 CAPLUS

CN Quinoline, 3-[(2-chlorophenyl)sulfonyl]-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 607742-57-4 CAPLUS


CN Quinoline, 3-[(3-chlorophenyl)sulfonyl]-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

10/509078




● HCl

RN 607742-58-5 CAPLUS  
CN Quinoline, 3-[(2-fluorophenyl)sulfonyl]-8-(1-piperazinyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-59-6 CAPLUS  
CN Quinoline, 3-[(4-chlorophenyl)sulfonyl]-8-(1-piperazinyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

10/509078

RN 607742-60-9 CAPLUS


CN Quinoline, 3-[(3-fluorophenyl)sulfonyl]-8-(1-piperazinyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-61-0 CAPLUS

CN Quinoline, 3-[[4-bromo-2-(trifluoromethoxy)phenyl]sulfonyl]-8-(1-  
piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 607742-62-1 CAPLUS


CN Quinoline, 8-(1-piperazinyl)-3-[[3-(trifluoromethyl)phenyl]sulfonyl]-,  
monohydrochloride (9CI) (CA INDEX NAME)

10/509078




● HCl

RN 607742-63-2 CAPLUS  
CN Quinoline, 7-chloro-3-(phenylsulfonyl)-8-(1-piperazinyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-64-3 CAPLUS  
CN Quinoline, 6-methyl-3-(phenylsulfonyl)-8-(1-piperazinyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

10/509078

RN 607742-65-4 CAPLUS  
CN Quinoline, 8-[(3R)-3-methyl-1-piperazinyl]-3-(phenylsulfonyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 607742-66-5 CAPLUS  
CN Quinoline, 8-[(3S)-3-methyl-1-piperazinyl]-3-(phenylsulfonyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 607742-68-7 CAPLUS  
CN Quinoline, 8-[(2S)-2-methyl-1-piperazinyl]-3-(phenylsulfonyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/509078



● HCl

RN 607742-70-1 CAPLUS


CN Quinoline, 8-(4-ethyl-1-piperazinyl)-3-(phenylsulfonyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607742-71-2 CAPLUS

CN Quinoline, 3-[(2-methylphenyl)sulfonyl]-8-(1-piperazinyl)- (9CI) (CA  
INDEX NAME)






10/509078


RN 607742-72-3 CAPLUS

CN Quinoline, 3-[(2-methoxyphenyl)sulfonyl]-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 607742-73-4 CAPLUS

CN Quinoline, 3-[(4-methylphenyl)sulfonyl]-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 607742-74-5 CAPLUS


CN Quinoline, 3-[(4-fluorophenyl)sulfonyl]-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 607742-75-6 CAPLUS

CN Quinoline, 8-(1-piperazinyl)-3-[[2-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)


10/509078



RN 607742-76-7 CAPLUS  
CN Quinoline, 3-[(2-methylphenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)- (9CI)  
(CA INDEX NAME)




RN 607742-77-8 CAPLUS  
CN Quinoline, 3-[(2-methoxyphenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)- (9CI)  
(CA INDEX NAME)




RN 607742-78-9 CAPLUS  
CN Quinoline, 3-[(4-methylphenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)- (9CI)  
(CA INDEX NAME)


10/509078



RN 607742-79-0 CAPLUS  
CN Quinoline, 3-[(4-fluorophenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)- (9CI)  
(CA INDEX NAME)




RN 607742-80-3 CAPLUS  
CN Quinoline, 3-[(3-fluorophenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)- (9CI)  
(CA INDEX NAME)




RN 607742-81-4 CAPLUS  
CN Quinoline, 3-[(2-fluorophenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)- (9CI)  
(CA INDEX NAME)


10/509078



RN 607742-82-5 CAPLUS  
CN Quinoline, 3-[(4-chlorophenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)- (9CI)  
(CA INDEX NAME)




RN 607742-83-6 CAPLUS  
CN Quinoline, 3-[(3-chlorophenyl)sulfonyl]-8-(4-methyl-1-piperazinyl)- (9CI)  
(CA INDEX NAME)



RN 607742-84-7 CAPLUS  
CN Quinoline, 8-(4-methyl-1-piperazinyl)-3-[[2-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)


10/509078



RN 607742-85-8 CAPLUS

CN Quinoline, 3-[(2-methylphenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607742-86-9 CAPLUS

CN Quinoline, 3-[(2-methoxyphenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 607742-87-0 CAPLUS

CN Quinoline, 3-[(4-methylphenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-  
(9CI) (CA INDEX NAME)

10/509078


Absolute stereochemistry.



RN 607742-88-1 CAPLUS

CN Quinoline, 3-[(4-fluorophenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607742-89-2 CAPLUS

CN Quinoline, 3-[(4-fluorophenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/509078

RN 607742-90-5 CAPLUS

CN Quinoline, 3-[(2-fluorophenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607742-92-7 CAPLUS

CN Quinoline, 3-[(4-chlorophenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 607742-93-8 CAPLUS

CN Quinoline, 3-[(3-chlorophenyl)sulfonyl]-8-[(3S)-3-methyl-1-piperazinyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/509078



RN 607742-94-9 CAPLUS

CN Quinoline, 8-[(3S)-3-methyl-1-piperazinyl]-3-[[2-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607742-95-0 CAPLUS

CN Quinoline, 8-[(2R)-2-methyl-1-piperazinyl]-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 607742-96-1 CAPLUS


CN Quinoline, 8-[(2R,5S)-2,5-dimethyl-1-piperazinyl]-3-(phenylsulfonyl)-,



10/509078


rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 607742-97-2 CAPLUS

CN Quinoline, 8-(3,3-dimethyl-1-piperazinyl)-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 607742-99-4 CAPLUS


CN Quinoline, 8-[4-(1-methylethyl)-1-piperazinyl]-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 607743-00-0 CAPLUS


CN Quinoline, 8-[4-(2-methylpropyl)-1-piperazinyl]-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

10/509078



RN 607743-01-1 CAPLUS


CN Quinoline, 8-[4-(2,2-dimethylpropyl)-1-piperazinyl]-3-(phenylsulfonyl)-  
(9CI) (CA INDEX NAME)



RN 607743-02-2 CAPLUS

CN Quinoline, 8-[(3R)-3,4-dimethyl-1-piperazinyl]-3-(phenylsulfonyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 607743-03-3 CAPLUS

CN Quinoline, 8-[(3S)-3,4-dimethyl-1-piperazinyl]-3-(phenylsulfonyl)- (9CI)  
(CA INDEX NAME)


10/509078

Absolute stereochemistry.



RN 607743-42-0 CAPLUS


CN Quinoline, 8-(4-methyl-1-piperazinyl)-3-(phenylsulfonyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 607743-46-4 CAPLUS


CN Quinoline, 3-[(2-chlorophenyl)sulfonyl]-8-(1-piperazinyl)- (9CI) (CA  
INDEX NAME)




RN 607743-47-5 CAPLUS

10/509078


CN Quinoline, 3-[(3-chlorophenyl)sulfonyl]-8-(1-piperazinyl)- (9CI) (CA  
INDEX NAME)



RN 607743-48-6 CAPLUS  
CN Quinoline, 3-[(2-fluorophenyl)sulfonyl]-8-(1-piperazinyl)- (9CI) (CA  
INDEX NAME)




RN 607743-49-7 CAPLUS  
CN Quinoline, 3-[(4-chlorophenyl)sulfonyl]-8-(1-piperazinyl)- (9CI) (CA  
INDEX NAME)




RN 607743-50-0 CAPLUS  
CN Quinoline, 3-[(3-fluorophenyl)sulfonyl]-8-(1-piperazinyl)- (9CI) (CA  
INDEX NAME)

10/509078




RN 607743-51-1 CAPLUS

CN Quinoline, 3-[[4-bromo-2-(trifluoromethoxy)phenyl]sulfonyl]-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 607743-52-2 CAPLUS


CN Quinoline, 8-(1-piperazinyl)-3-[[3-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 607743-53-3 CAPLUS

CN Quinoline, 7-chloro-3-(phenylsulfonyl)-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)

10/509078




RN 607743-54-4 CAPLUS  
CN Quinoline, 6-methyl-3-(phenylsulfonyl)-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 607743-55-5 CAPLUS  
CN Quinoline, 8-[(3R)-3-methyl-1-piperazinyl]-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607743-56-6 CAPLUS  
CN Quinoline, 8-[(3S)-3-methyl-1-piperazinyl]-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/509078



RN 607743-58-8 CAPLUS


CN Quinoline, 8-[(2S)-2-methyl-1-piperazinyl]-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 607743-59-9 CAPLUS

CN Quinoline, 8-(4-ethyl-1-piperazinyl)-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



=> file caold  
COST IN U.S. DOLLARS

SINCE FILE

TOTAL

10/509078

	ENTRY	SESSION
FULL ESTIMATED COST	26.82	207.38
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.90	-3.90

FILE 'CAOLD' ENTERED AT 12:14:51 ON 01 APR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966  
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s l3  
L5 0 L3

	SINCE FILE	TOTAL
	ENTRY	SESSION
COST IN U.S. DOLLARS		
FULL ESTIMATED COST	0.45	207.83
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-3.90

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 12:15:08 ON 01 APR 2007